Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 9 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 11825819

    Crnn loss of function rodent model

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted
  2. US 11820826

    Anti-NPR1 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  3. US 11820815

    Human antibodies to human delta like ligand 4

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  4. US 11820982

    Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  5. US 11814428

    Anti-PTCRA antibody-drug conjugates and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted
  6. US 11806398

    Citrate buffered VEGF antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  7. US 11787867

    Anti-GITR antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  8. US 11786606

    Site-specific quantitation of drug conjugations

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  9. US 11786603

    Optimized transglutaminase site-specific antibody conjugation

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  10. US 11778995

    Genetically modified non-human animals and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted
  11. US 11780907

    Human antibodies to influenza hemagglutinin

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted
  12. US 11779633

    Glucagon-like peptide 1 receptor agonists and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted
  13. US 11771762

    Anti-ErbB3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted
  14. US 11773393

    Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted
  15. US 11773156

    Anti-hemagglutinin antibodies and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted
  16. US 11771743

    Methods for preventing or treating allergy by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted
  17. US 11766032

    Genetically modified non-human animals expressing human EPO

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 26, 2023 · Expires Sep 21, 2043

    granted
  18. US 11767526

    Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 26, 2023 · Expires Sep 21, 2043

    granted
  19. US 11767358

    Human antibodies to Bet v 1 and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 26, 2023 · Expires Sep 21, 2043

    granted
  20. US 11769597

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 26, 2023 · Expires Sep 21, 2043

    granted
  21. US 11760775

    Steroids and protein-conjugates thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 19, 2023 · Expires Sep 14, 2043

    granted
  22. US 11759476

    Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 19, 2023 · Expires Sep 14, 2043

    granted
  23. US 11753628

    HSD17B13 variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted
  24. US 11753459

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted